



Jackson Kim, MD

Clinical Assistant Professor, Medicine - Nephrology

CLINICAL OFFICE (PRIMARY)

- **Nephrology**

300 Pasteur Dr Rm S161

MC 5114

Stanford, CA 94305

Tel (650) 723-6247 Fax (650) 725-8418

Bio

BIO

Dr. Kim is a Clinical Assistant Professor in the Division of Nephrology at Stanford Health Care.

Dr. Kim diagnoses and treats a range of conditions affecting the kidneys, including glomerulonephritis, nephrotic syndrome, chronic kidney disease, and genetic kidney disease. He creates a customized, comprehensive treatment plan for every patient he serves.

Dr. Kim has a keen research interest in glomerular kidney disease, particularly glomerulonephritis. He has authored manuscripts, conducted case studies, and published his work in several peer-reviewed journals.

CLINICAL FOCUS

- Nephrology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Nephrology

PROFESSIONAL EDUCATION

- Residency: LAC USC Medical Center Internal Medicine Residency (2020) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2025)
- Fellowship: Stanford University Nephrology Fellowship (2022) CA
- Medical Education: Tufts University School of Medicine (2017) MA

Research & Scholarship

CLINICAL TRIALS

- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy, Recruiting

- Atacicept in Multiple Glomerular Diseases, Recruiting
- Belimumab With Rituximab for Primary Membranous Nephropathy, Recruiting
- Nephrotic Syndrome Study Network, Recruiting
- Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN), Recruiting
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy, Not Recruiting
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis, Not Recruiting
- Atacicept in Subjects With IgA Nephropathy, Not Recruiting
- Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN), Not Recruiting
- Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN), Not Recruiting
- Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy, Not Specified

Publications

PUBLICATIONS

- **Current trial landscape of IgA nephropathy therapy.** *Med (New York, N.Y.)*
Kim, J., Kamal, F., Lafayette, R.
2026; 7 (1): 100940
- **How should we best manage the consequences of nephron loss in IgAN?** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*
Kim, J., Kamal, F., Yeung, B., Lafayette, R.
2025
- **Current Biomarkers of IgA Nephropathy.** *Seminars in nephrology*
Kamal, F., Kim, J., Lafayette, R.
2025: 151572
- **Midodrine Is an Effective Therapy for Resistant Intradialytic Hypotension: COMMENTARY.** *Kidney360*
Kim, J. P., Chang, T. I.
2023; 4 (3): 306-307